Key facts
- Novo Nordisk's investigational drug zenagamtide showed significant A1C reductions in type 2 diabetes patients.
- Up to 89.1% of participants achieved an A1C below 7% with zenagamtide.
- Participants experienced body weight reduction of up to 14.6% with zenagamtide.
- Study results were presented at the ADA 2026 conference.
- Novo Nordisk will present new data on Wegovy across cardiometabolic conditions at the ADA 2026 Scientific Sessions.
A phase 2 study of Novo Nordisk's investigational drug, zenagamtide, revealed significant improvements in blood sugar control for adults with type 2 diabetes. The once-weekly subcutaneous treatment resulted in statistically significant reductions in A1C levels compared to placebo. Notably, up to 89.1% of participants receiving zenagamtide achieved an A1C level below 7%. The study also indicated substantial body weight loss, with participants experiencing reductions of up to 14.6%. These findings were presented at the ADA 2026 conference. Separately, Novo Nordisk's Wegovy pill is reportedly exceeding expectations and outperforming projections, leading to questions about whether the stock is undervalued and presents a worthwhile investment opportunity. Novo Nordisk is also set to present new data on Wegovy across a range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions, including post hoc analyses exploring its impact on obstructive sleep apnea, liver health, and other obesity-related comorbidities.